Tyra Biosciences Q3 net loss $29.9M; cash $274.9M; dabogratinib trials on track

Tyra Biosciences, Inc.

2025-Q3 EPS reported -$1.45 vs consensus -$0.51 ▼ miss (-185.7%)

Cash, equivalents, and marketable securities of $274.9M as of Sep 30, 2025; runway through at least 2027.
Q3 net loss $29.9M vs $24.0M in Q3 2024; R&D spend $25.5M (up from $22.7M) on trial initiations.
First patients dosed in Phase 2 achondroplasia (BEACH301) and NMIBC (SURF302) studies; interim data expected 2026.
FDA cleared IND for dabogratinib in low-grade upper tract urothelial carcinoma (SURF303); Phase 2 start in 2026.
Upcoming milestones: SURF302 3-month CR data in 1H 2026; BEACH301 safety sentinel results in 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.